Key Takeaways Butterfly Network's AI-powered ultrasound showed 0.94 AUROC accuracy in detecting aortic stenosis.Omnicell launched MedTrack and MedVision to improve medication tracking, safety, and efficiency.BFLY and OMCL are Buy-ranked stocks with projected earnings and revenue growth into 2025 and 2026.The global AI in healthcare market is experiencing explosive growth. According to a Fortune Business Insights report, the market is projected to scale from $39.25 billion in 2025 to approximately $504.17 bi ...

Omnicell (OMCL) closed the last trading session at $31.86, gaining 1.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $44.4 indicates a 39.4% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $9.13. While the lowest estimate of $34.00 indicates a 6.7% increase from the current price level, the most optimistic analyst expects t ...

Omnicell (OMCL) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this Omnicell Inc., should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earni ...

Group 1 - Omnicell (OMCL) closed at $33.09, with a 14.1% gain over the past four weeks, and a mean price target of $44.4 indicating a 34.2% upside potential [1] - The average price targets range from a low of $34.00 to a high of $55.00, with a standard deviation of $9.13, suggesting variability in analyst estimates [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 33.6% over the past month, with three estimates going higher and no negative revisions [12] - OMCL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-33043 OMNIC ...

Group 1 - Omnicell held its Second Quarter 2025 Financial Results Conference Call, featuring key executives including the CEO and CFO [2][3] - The call included forward-looking statements regarding financial projections and market outlook based on current expectations [3] Group 2 - The actual results may differ materially from the forward-looking statements due to various risks and uncertainties [4]

Group 1 - The stock of Omnicell (OMCL) closed at $31.01, showing a 3.9% increase over the past four weeks, with a mean price target of $44.8 indicating a potential upside of 44.5% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $9.73, where the lowest estimate is $34.00 (9.6% increase) and the highest is $57.00 (83.8% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.9%, with one estimate moving higher and no negative revisions [12] - OMCL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does suggest a positive direction for price movement [14]

Core Insights - Michael (Mike) Dion is an FP&A leader with diverse finance experience across various industries including Telecom, Media and Entertainment, Hospitality, and Construction [1] - He founded Mike's F9 Finance, a platform aimed at helping finance professionals advance their careers [1] - Dion's investment strategy focuses on identifying value opportunities where market reactions to news are disproportionate, emphasizing strong fundamentals and a preference for dividend-paying stocks [1] - He highlights the importance of cash flow for both companies and investors, indicating it is critical at all levels [1]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $291 million, an increase of $14 million or 5% year-over-year and an increase of $21 million or 8% compared to the previous quarter [6][18] - GAAP earnings per share for Q2 2025 were $0.12, compared to $0.08 in Q2 2024 and a loss of $0.15 in the prior quarter [6][20] - Non-GAAP gross margin for Q2 2025 was 44.7%, an increase of 50 basis points year-over-year and 260 basis points from the prior quarter [19] - Non-GAAP earnings per share for Q2 2025 were $0.45, down from $0.51 in the same period last year and up from $0.26 in the prior quarter [20] - Free cash flow for Q2 2025 was $27 million, an increase of $17 million compared to the prior quarter [20] Business Line Data and Key Metrics Changes - Product revenue for Q2 2025 was $163 million, an increase of $7 million year-over-year and an increase of $18 million over the previous quarter [18] - Service revenue for Q2 2025 was $127 million, an increase of $7 million from the previous year and an increase of $3 million over the previous quarter [18] Market Data and Key Metrics Changes - The company is focused on expanding its market presence across both inpatient and outpatient settings, including nursing units, operating rooms, and various types of pharmacies [8] - The installed customer base has grown significantly, contributing to strong demand for the company's products [5] Company Strategy and Development Direction - The company is evolving from a device-centric model to an end-to-end medication and medical supplies management technology platform, integrating automation and intelligence [5][10] - Key strategic initiatives include expanding market presence, scaling recurring revenue, and accelerating the Omnisphere technology platform [8][10] - The launch of new products like MedVision and MedTrak aims to enhance visibility and operational efficiency in medication management [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in customer demand tracking expectations despite macroeconomic uncertainties [4][8] - The company is navigating tariff impacts, with an expected net quarterly impact of approximately $6 million for 2025 [23][24] - Future growth is anticipated to be driven by innovation and providing ROI solutions to customers [16] Other Important Information - The company unveiled an innovation lab in Austin, Texas, dedicated to addressing customer pain points through rapid prototyping [11] - Omnisphere received HITRUST CSF certification, affirming the company's commitment to cybersecurity [10] Q&A Session Summary Question: Competitive landscape and hospital purchasing behavior - Management noted that hospitals are still in the market and their buying behavior remains steady despite macroeconomic headwinds [30][39] Question: Impact of Medicaid cuts on purchasing - Management indicated that hospitals are still assessing the full impact of legislative changes and have not seen a change in purchasing behavior yet [36][39] Question: Demand for IV compounding products - Management confirmed that the IV compounding product has gained momentum and has a backlog of customers [45] Question: Software solutions for clinics - Management highlighted the importance of integrated solutions for clinics and outpatient settings, with MedVision being a key offering [52] Question: Tariff assumptions in guidance - Management confirmed that guidance assumes a 30% tariff rate for the second half of the year [82]

Omnicell (OMCL) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +45.16%. A quarter ago, it was expected that this Omnicell Inc. would post earnings of $0.16 per share when it actually produced earnings of $0.26, delivering a surprise of +62.5%.Over the last four quarters, the company ...